DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
1. A method of treating type 2 diabetes mellitus comprising orally administering to a patient in need thereof a pharmaceutical composition comprising:
(a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dosage of 2.5 mg or 5 mg,
(b) metformin hydrochloride,
(c) one or more pharmaceutical excipients, and
(d) a basic amino acid having an intramolecular amino group and alkaline characteristics, which basic amino acid is present in an amount sufficient to suppress degradation of said 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine,
wherein the pharmaceutical composition is a tablet comprising a film-coat; and
wherein the pharmaceutical composition comprises the following amounts: 0.1-0.5% of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, 47-85% of metformin hydrochloride, and 0.07-2.2% of the basic amino acid, wherein each of the foregoing percentage amounts are based on the weight of total coated tablet mass.
2. The method according to claim 1 , wherein the basic amino acid having an intramolecular amino group and alkaline characteristics is selected from L-arginine, L-lysine and L-histidine.
3. The method according to claim 1 , wherein 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is present in a dosage strength of 5 mg.
4. The method according to claim 1 , wherein 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is present in a dosage strength of 2.5 mg.
5. The method according to claim 1 , wherein metformin hydrochloride is present in a dosage range from about 100 mg to about 1500 mg.
6. The method according to claim 5 , wherein metformin hydrochloride is present in a dosage strength of 250, 500, 625, 750, 850, or 1000 mg.
7. The method according to claim 5 , wherein metformin hydrochloride is present in a dosage strength of 500 mg, 850 mg, or 1000 mg.
8. The method according to claim 1 , wherein the basic amino acid having an intramolecular amino group and alkaline characteristics is L-arginine, and wherein the L-arginine is present from about 1 mg to about 25 mg.
9. The method according to claim 1 comprising the active ingredients in a dosage strength of 2.5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine and 500 mg of metformin hydrochloride.
10. The method according to claim 1 comprising the active ingredients in a dosage strength of 2.5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine and 850 mg of metformin hydrochloride.
11. The method according to claim 1 comprising the active ingredients in a dosage strength of 2.5 mg of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine and 1000 mg of metformin hydrochloride.
12. A method of treating type 2 diabetes mellitus comprising orally administering to a patient in need thereof a solid pharmaceutical composition which is a mono-layer tablet comprising:
1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dosage of 2.5 mg,
metformin hydrochloride,
L-arginine in an amount sufficient to suppress degradation of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, and one or more fillers and one or more binders,
wherein the percentage of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine is about 0.2%-0.4%, by weight of total tablet core and,
wherein the DPP-4 inhibitor and L-arginine are comprised in a weight ratio of from about 1:10 to about 10:1.
13. The method according to claim 12 , wherein metformin hydrochloride is present in a dosage range from about 100 mg to about 1500 mg.
14. The method according to claim 13 , wherein metformin hydrochloride is present in a dosage strength of 250, 500, 625, 750, 850, or 1000 mg.
15. The method according to claim 13 , wherein metformin hydrochloride is present in a dosage strength of 500 mg, 850 mg, or 1000 mg.
16. The method according to claim 12 , wherein the L-arginine is present from about 1 mg to about 25 mg.
17. The method according to claim 12 comprising 500 mg of metformin hydrochloride.
18. The method according to claim 12 comprising 850 mg of metformin hydrochloride.
19. The method according to claim 12 comprising 1000 mg of metformin hydrochloride.
20. A method of achieving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a pharmaceutical composition comprising:
(a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dosage of 2.5 mg or 5 mg,
(b) metformin hydrochloride,
(c) one or more pharmaceutical excipients, and
(d) a basic amino acid having an intramolecular amino group and alkaline characteristics, which basic amino acid is present in an amount sufficient to suppress degradation of said 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine,
wherein the pharmaceutical composition is a tablet comprising a film-coat; and
wherein the pharmaceutical composition comprises the following amounts: 0.1-0.5% of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, 47-85% of metformin hydrochloride, and 0.07-2.2% of the basic amino acid, wherein each of the foregoing percentage amounts are based on the weight of total coated tablet mass.